Ovid Therapeutics Stock Performance
| OVID Stock | USD 1.65 0.11 6.25% |
On a scale of 0 to 100, Ovid Therapeutics holds a performance score of 3. The company holds a Beta of 2.93, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ovid Therapeutics will likely underperform. Please check Ovid Therapeutics' total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Ovid Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ovid Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak forward indicators, Ovid Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Duncan Barbara Gayle of 30000 shares of Ovid Therapeutics at 3.68 subject to Rule 16b-3 | 10/17/2025 |
2 | How strong is Ovid Therapeutics Inc. stock balance sheet - Quarterly Earnings Summary Real-Time Buy Signal Notifications - nchmf.gov.vn | 10/23/2025 |
3 | MannKind Tops Q3 Earnings and Revenue Estimates | 11/05/2025 |
4 | Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | 11/12/2025 |
5 | Historical volatility pattern of Ovid Therapeutics Inc. visualized - July 2025 Setups Expert-Curated Trade Recommendations - newser.com | 11/18/2025 |
6 | Ovid Therapeutics HC Wainwright Raises Price Target to 2.00 OVID Stock News - GuruFocus | 11/24/2025 |
7 | Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech | 12/04/2025 |
8 | Disposition of 1250 shares by Takeda Pharmaceutical Co Ltd of Ovid Therapeutics subject to Rule 16b-3 | 12/08/2025 |
9 | Acquisition by Levin Jeremy M of tradable shares of Ovid Therapeutics subject to Rule 16b-3 | 12/11/2025 |
10 | Disposition of tradable shares by Levin Jeremy M of Ovid Therapeutics subject to Rule 16b-3 | 12/15/2025 |
11 | Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 , OV350 Intravenous | 12/18/2025 |
12 | What is Lifesci Capitals Estimate for OVID FY2025 Earnings | 12/24/2025 |
| Begin Period Cash Flow | 29 M | |
| Total Cashflows From Investing Activities | 54.6 M |
Ovid Therapeutics Relative Risk vs. Return Landscape
If you would invest 167.00 in Ovid Therapeutics on October 7, 2025 and sell it today you would earn a total of 9.00 from holding Ovid Therapeutics or generate 5.39% return on investment over 90 days. Ovid Therapeutics is currently generating 0.2678% in daily expected returns and assumes 6.2038% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Ovid, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ovid Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ovid Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ovid Therapeutics, and traders can use it to determine the average amount a Ovid Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0432
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | OVID | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Ovid Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ovid Therapeutics by adding it to a well-diversified portfolio.
Ovid Therapeutics Fundamentals Growth
Ovid Stock prices reflect investors' perceptions of the future prospects and financial health of Ovid Therapeutics, and Ovid Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ovid Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (94.87) % | ||||
| Current Valuation | 113.49 M | ||||
| Shares Outstanding | 71.21 M | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 18.96 X | ||||
| Revenue | 566 K | ||||
| Gross Profit | 6.61 M | ||||
| EBITDA | (57.77 M) | ||||
| Net Income | (26.43 M) | ||||
| Cash And Equivalents | 152.37 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 14.76 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 16.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (55.96 M) | ||||
| Earnings Per Share | (0.50) X | ||||
| Market Capitalization | 125.33 M | ||||
| Total Asset | 92.17 M | ||||
| Retained Earnings | (304.3 M) | ||||
| Working Capital | 45.42 M | ||||
| Current Asset | 74.21 M | ||||
| Current Liabilities | 5.13 M | ||||
About Ovid Therapeutics Performance
By analyzing Ovid Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Ovid Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ovid Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ovid Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.87) | (0.92) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.45) | (0.47) |
Things to note about Ovid Therapeutics performance evaluation
Checking the ongoing alerts about Ovid Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ovid Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ovid Therapeutics had very high historical volatility over the last 90 days | |
| Ovid Therapeutics may become a speculative penny stock | |
| Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 566 K. Net Loss for the year was (26.43 M) with profit before overhead, payroll, taxes, and interest of 6.61 M. | |
| Ovid Therapeutics currently holds about 152.37 M in cash with (55.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ovid Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: What is Lifesci Capitals Estimate for OVID FY2025 Earnings |
- Analyzing Ovid Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ovid Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Ovid Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ovid Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ovid Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ovid Therapeutics' stock. These opinions can provide insight into Ovid Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ovid Stock analysis
When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |